Escient Pharmaceuticals, Inc.

Receptos, Inc.

Celgene International Ii Sarl

Adam Richard Yeager

Liming Huang

Esther Martinborough

Marcus F Boehm

Junko Tamiya

Manisha Moorjani

Enugurthi Brahmachary

Thomas Fowler

Brandon Selfridge

Marcos Sainz

Premji Meghani

Andrew Richard Novak

Marion Lanier

Michael Knaggs

Robert Peach

Michael Allen Hanson

Jennifer L Brooks

Fiona Lorraine Scott

Gregg Alan Timony

Philip Turnbull

Daniel Glynn

Mark Mills

Lin Zhang

Marcos Steinberg

Junhua Fan

Kevan Grant

Matthew Richard Crittall

Greg P Iacobini

Brahmachary Enugurthi

Tom Fowler

Hanae Benelkebir

Raffaele Pasceri

Maria Ieva

Yang Tran

Methods are provided for modulating MRGPR X2 generally, or for treating a MRGPR X2 dependent condition more specifically, by contacting the MRGPR X2 or administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein W, Z, R, R, R, R, R, Rand Rare as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.

Modulators of mas-related g-protein receptor X2 and related products and methods

Methods are provided for modulating MRGPR X2 generally, or for treating a MRGPR X2 or a MRGPR X2 ortholog dependent condition, more specifically, by contacting the MRGPR X2 or the MRGPR X2 ortholog by administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein W, Z, R, R, R, R, R, Rand Rare as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.

Methods are provided for modulating MRGPRX2 generally, or for treating a MRGPRX2 dependent condition more specifically, by contacting the MRGPRX2 or administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein A, B, C, D, E, G, W, Y, Z, R, R, R, R, R, R, Rand Rare as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.

Modulators of mas-related G-protein receptor X2 and related products and methods

Methods are provided for modulating MRGPRX2 generally, or for treating a MRGPRX2 or a MRGPRX2 ortholog dependent condition, more specifically, by contacting the MRGPRX2 or the MRGPRX2 ortholog by administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein W, Z, R, R, R, R, R, Rand Rare as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.

Modulators of Mas-related G-protein receptor X2 and related products and methods

Methods are provided for modulating MRGPRX2 or a MRGPRX2 ortholog generally, or for treating a MRGPRX2 or a MRGPRX2 ortholog dependent condition more specifically, by contacting the MRGPRX2 or the MRGPRX2 ortholog by administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein W, Z, R, R, R, R, R, Rand Rare as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.

Methods are provided for modulating MRGPRX2 generally, or for treating a MRGPRX2 dependent condition more specifically, by contacting the MRGPRX2 or administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein D, W, Z, R, Rand Rare as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.

Methods are provided for modulating MRGPR X4 generally, or for treating a MRGPR X4 dependent condition more specifically, by contacting the MRGPR X4 or administering to a subject in need thereof, respectively, an effective amount of a compound having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein n, x, A, Q, Q, Z, R, R, R, R, Rand Rare as defined herein. Pharmaceutical compositions containing such compounds, as well as to compounds themselves, are also provided.

Modulators of Mas-related G-protein receptor X4 and related products and methods

Methods are provided for modulating MRGPR X4 generally, or for treating a MRGPR X4 dependent condition more specifically, by contacting the MRGPR X4 or administering to a subject in need thereof, respectively, an effective amount of a compound having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein m, n, p, t, A, B, Z, R, Rand Rare as defined herein. Pharmaceutical compositions containing such compounds, as well as to compounds themselves, are also provided.

Modulators of mas-related g-protein receptor X4 and related products and methods

Modulators of mas-related G-protein receptor X4 and related products and methods

Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as products containing such compounds, and methods of their use and synthesis. Such compounds have the structure of Formula (I) below: (I) or pharmaceutically acceptable salts thereof, wherein A, J, W, Y, Z, R, R, Rand Rare as defined herein. 

GLP-1 receptor modulators

Compounds are provided having the structure of the following Formula I: where R, R, R, Rand Rare as defined herein. Pharmaceutical compositions comprising such compounds, as well as methods related to their manufacture and use, are also provided.

CXCR3 receptor agonists

Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where '' represents either or both the R and S form of the compound): where A, B, C, Y, Y, Z, R, R, R, R, R, W, n, p and q are as defined herein.

Growing community of inventors

La Mesa, CA, United States of America

Adam Richard Yeager